In breast cancer hormone therapy—if the patient is not suffering from triple-negative breast cancer (TNBC)—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are proven to be potential targets, and several biomarkers are successfully used for revealing their presence or absence in a given tumor [3]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.